1720 related articles for article (PubMed ID: 14564000)
1. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
2. Medicine. Gene therapy--new challenges ahead.
Williams DA; Baum C
Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994
[TBL] [Abstract][Full Text] [Related]
3. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.
McCormack MP; Rabbitts TH
N Engl J Med; 2004 Feb; 350(9):913-22. PubMed ID: 14985489
[No Abstract] [Full Text] [Related]
4. Gene therapy resumes.
Novak K
Nat Rev Cancer; 2002 Nov; 2(11):813. PubMed ID: 12442759
[No Abstract] [Full Text] [Related]
5. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
6. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy insertional mutagenesis insights.
Davé UP; Jenkins NA; Copeland NG
Science; 2004 Jan; 303(5656):333. PubMed ID: 14726584
[No Abstract] [Full Text] [Related]
8. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.
Avilés Mendoza GJ; Seidel NE; Otsu M; Anderson SM; Simon-Stoos K; Herrera A; Hoogstraten-Miller S; Malech HL; Candotti F; Puck JM; Bodine DM
Mol Ther; 2001 Apr; 3(4):565-73. PubMed ID: 11319919
[TBL] [Abstract][Full Text] [Related]
9. [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome].
Fischer A; Hacein-Bey-Abina S; Lagresle C; Garrigue A; Cavazana-Calvo M
Bull Acad Natl Med; 2005 May; 189(5):779-85; discussion 786-8. PubMed ID: 16433450
[TBL] [Abstract][Full Text] [Related]
10. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.
Hacein-Bey-Abina S; Le Deist F; Carlier F; Bouneaud C; Hue C; De Villartay JP; Thrasher AJ; Wulffraat N; Sorensen R; Dupuis-Girod S; Fischer A; Davies EG; Kuis W; Leiva L; Cavazzana-Calvo M
N Engl J Med; 2002 Apr; 346(16):1185-93. PubMed ID: 11961146
[TBL] [Abstract][Full Text] [Related]
11. Progress toward the genetic treatment of the beta-thalassemias.
Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial.
Kaiser J
Science; 2003 Jan; 299(5606):495. PubMed ID: 12543948
[No Abstract] [Full Text] [Related]
13. Strategies for retrovirus-based correction of severe, combined immunodeficiency (SCID).
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
Methods Enzymol; 2012; 507():15-27. PubMed ID: 22365767
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy: is IL2RG oncogenic in T-cell development?
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Nature; 2006 Sep; 443(7109):E5; discussion E6-7. PubMed ID: 16988660
[TBL] [Abstract][Full Text] [Related]
15. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
[TBL] [Abstract][Full Text] [Related]
16. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.
Kustikova O; Fehse B; Modlich U; Yang M; Düllmann J; Kamino K; von Neuhoff N; Schlegelberger B; Li Z; Baum C
Science; 2005 May; 308(5725):1171-4. PubMed ID: 15905401
[TBL] [Abstract][Full Text] [Related]
17. Risks and benefits of gene therapy.
Noguchi P
N Engl J Med; 2003 Jan; 348(3):193-4. PubMed ID: 12529458
[No Abstract] [Full Text] [Related]
18. [Hematopoietic malignancies and gene therapy].
Ozawa K
Gan To Kagaku Ryoho; 2003 Apr; 30(4):478-82. PubMed ID: 12722677
[TBL] [Abstract][Full Text] [Related]
19. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
20. Good news for gene therapy.
Berns A
N Engl J Med; 2004 Apr; 350(16):1679-80. PubMed ID: 15084702
[No Abstract] [Full Text] [Related]
[Next] [New Search]